Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease

  • Chaparro, M.
  • Garre, A.
  • Guerra, Veloz, M.F.
  • Vázquez Morón, J.M.
  • De Castro, M.L.
  • Leo, E.
  • Rodriguez, E.
  • Carbajo, A.Y.
  • Riestra, S.
  • Jiménez, I.
  • Calvet, X.
  • Bujanda, L.
  • Rivero, M.
  • Gomollón, F.
  • Benítez, J.M.
  • Bermejo, F.
  • Alcaide, N.
  • Gutiérrez, A.
  • Mañosa, M.
  • Iborra, M.
  • Lorente, R.
  • Rojas-Feria, M.
  • Barreiro-de Acosta, M.
  • Kolle, L.
  • Van Domselaar, M.
  • Amo, V.
  • Argüelles, F.
  • Ramírez, E.
  • Morell, A.
  • Bernardo, D.
  • Gisbert, J.P.
BACKGROUND AND AIMS: To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®. METHODS: Patients under Remicade® who were in clinical remission with standard dosage at study entry were included. The ''switch cohort'' [SC] comprised patients who made the switch from Remicade® to CT-P13, and the ''non-switch'' cohort [NC] patients remained under Remicade®. RESULTS: A total of 476 patients were included: 199 [42%] in the SC and 277 [58%] in the NC. The median follow-up was 18 months in the SC and 23 months in the NC [p < 0.01]. Twenty-four out of 277 patients relapsed in the NC; the incidence of relapse was 5% per patient-year. The cumulative incidence of relapse was 2% at 6 months and 10% at 24 months in this group. Thirty-eight out of 199 patients relapsed in the SC; the incidence rate of relapse was 14% per patient-year. The cumulative incidence of relapse was 5% at 6 months and 28% at 24 months. In the multivariate analysis, the switch to CT-P13 was associated with a higher risk of relapse (HR = 3.5, 95% confidence interval [CI] = 2-6). Thirteen percent of patients had adverse events in the NC, compared with 6% in the SC [p < 0.05]. CONCLUSIONS: Switching from Remicade® to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. The nocebo effect might have influenced this result. Switching from Remicade® to CT-P13 was safe.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Incidence, clinical characteristics and management of inflammatory bowel disease in Spain: large-scale epidemiological study

  • Chaparro, M.
  • Garre, A.
  • Núñez Ortiz, A.
  • Diz-Lois Palomares, M. T.
  • Rodríguez, C.
  • Riestra, S.
  • Vela, M.
  • Benítez, J. M.
  • Fernández Salgado, E.
  • Sánchez Rodríguez, E.
  • Hernández, V.
  • Ferreiro-Iglesias, R.
  • Ponferrada Díaz, Á.
  • Barrio. J.
  • Huguet, J. M.
  • Sicilia, B.
  • Martín-Arranz, M. D.
  • Calvet, X.
  • Ginard, D.
  • Alonso-Abreu, I.
  • Fernández-Salazar, L.
  • Varela Trastoy, P.
  • Rivero, M.
  • Vera-Mendoza, I.
  • Vega, P.
  • Navarro, P.
  • Sierra, M.
  • Cabriada, J. L.
  • Aguas, M.
  • Vicente, R.
  • Navarro-Llavat, M.
  • Echarri, A.
  • Gomollón, F.
  • Guerra del Río, E.
  • Piñero, C.
  • Casanova, M. J.
  • Spicakova, K.
  • Ortiz de Zarate, J.
  • Torrella Cortés, E.
  • Gutiérrez, A.
  • Alonso-Galán, H.
  • Hernández-Martínez, Á.
  • Marrero, J. M.
  • Lorente Poyatos, R.
  • Calafat, M.
  • Martí Romero, L.
  • Robledo, P.
  • Bosch, O.
  • Jiménez, N.
  • Esteve Comas, M.
  • Duque, J. M.
  • Fuentes Coronel, A. M.
  • Sampedro, M. J.
  • Sesé Abizanda, E.
  • Herreros Martínez, B.
  • Pozzati, L.
  • Fernández Rosáenz, H.
  • Crespo Suarez, B.
  • López Serrano, P.
  • Lucendo, A. J.
  • Muñoz Vicente, M.
  • Bermejo, F.
  • Ramírez Palanca, J. J.
  • Menacho, M.
  • Carmona, A.
  • Camargo, R.
  • Torra Alsina, S.
  • Maroto, N.
  • Nerín de la Puerta, J.
  • Castro, E.
  • Marín-Jiménez, I.
  • Botella, B.
  • Sapiña, A.
  • Cruz, N.
  • Forcelledo, J. L. F.
  • Bouhmidi, A.
  • Castaño-Milla, C.
  • Opio, V.
  • Nicolás, I.
  • Kutz, M.
  • Abraldes Bechiarelli, A.
  • Gordillo, J.
  • Ber, Y.
  • Torres Domínguez, Y.
  • Novella Durán, M. T.
  • Rodríguez Mondéjar, S.
  • Martínez-Cerezo, F. J.
  • Kolle, L.
  • Sabat, M.
  • Ledezma, C.
  • Iyo E.
  • Roncero, Ó.
  • Irisarri, R.
  • Lluis, L.
  • Blázquez Gómez, I.
  • Zapata, E. M.
  • Alcalá, M. J.
  • Martínez Pascual, C.
  • Montealegre, M.
  • Mata, L.
  • Monrobel, A.
  • Hernández Camba, A.
  • Hernández, L.
  • Tejada, M.
  • Mir, A.
  • Galve, M. L.
  • Soler, M.
  • Hervías, D.
  • Gómez-Valero, J. A.
  • Barreiro de Acosta, M.
  • Rodríguez-Artalejo, F.
  • García-Esquinas, E.
  • Gisbert, J. P.
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100, 000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Probable overwintering of adult Hyalomma rufipes in Central Europe

  • Rudolf I.
  • Kejíková R.
  • Vojtíšek J.
  • Mendel J.
  • Penázziová K.
  • Hubálek Z.
  • Šikutová S.
  • Estrada-Peña A.
Hyalomma spp. ticks (Acari: Ixodidae) represent a public health threat because of their prominent role in the transmission of Crimean- Congo haemorrhagic fever (CCHF) virus. Moreover, these ticks can transmit other medically important arboviruses such as Thogoto, Dhori, West Nile, and Bhanja viruses; human pathogenic bacteria like Rickettsia conorii, R. aeschlimannii, and Anaplasma marginale; and protozoans like Theileria annulata and Babesia caballi (Huba ´lek and Rudolf, 2011). Many records of larval and nymphal H. marginatum ticks on birds migrating from North Africa and Southern Europe into Central and Northern Europe have been published.